Skip to main content

CytomX Therapeutics, Inc. (CTMX)

NASDAQ: CTMX · IEX Real-Time Price · USD
5.14 -0.05 (-0.96%)
Oct 15, 2021 4:00 PM EDT - Market closed
Market Cap338.16M
Revenue (ttm)66.42M
Net Income (ttm)-64.21M
Shares Out65.06M
EPS (ttm)-1.17
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume376,690
Open5.25
Previous Close5.19
Day's Range5.10 - 5.25
52-Week Range4.28 - 10.05
Beta0.71
AnalystsBuy
Price Target13.14 (+155.6%)
Est. Earnings DateNov 4, 2021

About CTMX

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gas...

IndustryBiotechnology
IPO DateOct 8, 2015
CEOSean McCarthy
Employees144
Stock ExchangeNASDAQ
Ticker SymbolCTMX
Full Company Profile

Financial Performance

In 2020, CTMX's revenue was $100.36 million, an increase of 74.58% compared to the previous year's $57.49 million. Losses were -$32.89 million, -67.83% less than in 2019.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for CTMX stock is "Buy." The 12-month stock price forecast is 13.14, which is an increase of 155.64% from the latest price.

Price Target
$13.14
(155.64% upside)
Analyst Consensus: Buy

News

CytomX Therapeutics Appoints Dr. Alan Ashworth to Board of Directors

SOUTH SAN FRANCISCO, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investiga...

1 week ago - GlobeNewsWire

CytomX Therapeutics Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., Aug. 17, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investig...

1 month ago - GlobeNewsWire

CytomX Therapeutics (CTMX) Reports Q2 Loss, Misses Revenue Estimates

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -15.38% and -10.16%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

CytomX Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investiga...

2 months ago - GlobeNewsWire

CytomX Therapeutics (CTMX) Expected to Beat Earnings Estimates: Should You Buy?

CytomX Therapeutics (CTMX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

CytomX Therapeutics to Announce Second Quarter 2021 Financial Results on August 5, 2021

SOUTH SAN FRANCISCO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investiga...

2 months ago - GlobeNewsWire

Here's Why CytomX Therapeutics (CTMX) is Poised for a Turnaround After Losing 15.8% in 4 Weeks

CytomX Therapeutics (CTMX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in ...

3 months ago - Zacks Investment Research

CytomX Therapeutics to Present at Jefferies Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigat...

4 months ago - GlobeNewsWire

CytomX Therapeutics (CTMX) Reports Q1 Loss, Misses Revenue Estimates

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 10.34% and -21.39%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

CytomX Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigat...

5 months ago - GlobeNewsWire

CytomX Therapeutics to Announce First Quarter 2021 Financial Results on May 6, 2021

SOUTH SAN FRANCISCO, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investig...

5 months ago - GlobeNewsWire

CytomX Therapeutics Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investi...

6 months ago - GlobeNewsWire

Co-Diagnostics, DocuSign, Dow, Nomura, Sea and More Monday Afternoon Analyst Calls

With the trading day about halfway over, the broad markets were pushing lower. The Dow Jones industrial average and S&P 500 were only down slightly to start the week, while the Nasdaq faced the worst of...

6 months ago - 24/7 Wall Street

CytomX Therapeutics to Host Virtual Investor Event on April 7, 2021

SOUTH SAN FRANCISCO, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investi...

6 months ago - GlobeNewsWire

CytomX Therapeutics (CTMX) Upgraded to Buy: What Does It Mean for the Stock?

CytomX Therapeutics (CTMX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

7 months ago - Zacks Investment Research

Moving Average Crossover Alert: CytomX Therapeutics (CTMX)

CytomX Therapeutics (CTMX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

7 months ago - Zacks Investment Research

CytomX Therapeutics to Present at Upcoming March Virtual Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investig...

7 months ago - GlobeNewsWire

CytomX Therapeutics Announces New Employment Inducement Grant

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investiga...

7 months ago - GlobeNewsWire

CytomX Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investiga...

7 months ago - GlobeNewsWire

UPDATE - CytomX Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives w...

8 months ago - GlobeNewsWire

CytomX Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives w...

8 months ago - GlobeNewsWire

Steven Cohen Snaps Up Stake in CytomX Therapeutics

Point72 Asset Management leader Steven Cohen (Trades, Portfolio) disclosed earlier this week his firm entered an 8.9% stake in CytomX Therapeutics Inc. (NASDAQ:CTMX).

8 months ago - GuruFocus

Why Editas Medicine, Inovio, Dyne, and CytomX Stocks Are Falling Today

All four biotechs announced the pricing of stock offerings.

Other symbols:EDITINO
8 months ago - The Motley Fool

CytomX Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives w...

8 months ago - GlobeNewsWire